Study summary
A fixed course of acalabrutinib and venetoclax beat chemotherapy
83.1%progression-free at 3 years with the three-drug regimen, vs 66.5% with chemo
What was tested
Fixed-duration acalabrutinib plus venetoclax, with or without obinutuzumab, against chemo-immunotherapy, for previously untreated CLL in fit adults.
What they found
- Progression-free survival at about 3 years was 76.5% with acalabrutinib-venetoclax, 83.1% with the three-drug combination, and 66.5% with chemo-immunotherapy.
What it means
Another all-targeted, time-limited option that avoids chemotherapy.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.